Neal Shore, MD, FACS

Articles

Dr Shore on the Rationale for the Duravelo-2 Trial in Metastatic Urothelial Cancer

November 8th 2024

Neal D. Shore, MD, FACS, discusses the Duravelo-1 and Duravelo-2 trials investigating zelenectide pevedotin in metastatic urothelial carcinoma.

Dr Shore on the Importance of a Multidisciplinary Team in Urologic Oncology

May 3rd 2024

Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.

Dr Shore on Key Clinical Trial Data in Biochemically Recurrent Prostate Cancer

March 11th 2024

Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.

Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

March 4th 2024

Our expert panel provide insightful discussion on the power of multidisciplinary expertise in advanced prostate cancer.

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

March 4th 2024

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.

Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

February 26th 2024

This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer.

Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

February 26th 2024

Expert perspectives on androgen receptor signaling and its role in fueling prostate cancer metastasis along with a whiteboarding animation depicting this process.

Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

February 19th 2024

Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

February 19th 2024

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice

Dr Shore on the Implications of the FDA Approval of Enzalutamide for nmCSPC

February 16th 2024

Neal Shore, MD, FACS, discusses the implications of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.

Dr Shore on the Background and Outcomes of the EMBARK Trial in nmCSPC

February 15th 2024

Neal Shore, MD, FACS, discusses the phase 3 EMBARK study of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

Optimizing Care of Patients With Advanced Prostate Cancer: Conclusion

February 9th 2024

Summarizes the main points and benefits of multidisciplinary prostate cancer care.

Clinical Case 4: Radiation Therapy

February 2nd 2024

Covers key factors in deciding on radiation treatment.

Clinical Case 3: Extensive Lymph Node Disease

February 2nd 2024

Discusses treatment options for advanced metastatic disease.

Clinical Case 2: Solitary Lymph Node

January 30th 2024

Looks at approaches for isolated lymph node involvement.

Clinical Case 1b: Elderly Patient Surgery

January 30th 2024

Examines the considerations for operating on older prostate cancer patients.

Clinical Case 1a: Elevated PSA

January 19th 2024

Reviews a case of a patient with high PSA but no other symptoms.

Supporting Professional Relationships

January 19th 2024

Explains the importance of respect and collaboration between care providers.

Patient Involvement in Decision Making

January 12th 2024

Focuses on patients being active participants in their treatment choices.

The Value of a Coordinated Care Team

January 12th 2024

Highlights the advantages of various providers working together for patient care.